Literature DB >> 27940077

The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine.

Megan J Moerke1, Andy Z X Zhu2, Rachel F Tyndale2, Martin A Javors3, Lance R McMahon4.   

Abstract

Quantitative analysis of antagonism is infrequently used to identify nAChRs mediating behavioral effects. Here, nicotine (0.032 mg/kg i.v.) was established as a discriminative stimulus in rhesus monkeys responding under a fixed ratio 5 schedule; pharmacokinetics and underlying nAChR mechanism(s) were examined. When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml. The ED50 value of nicotine to produce discriminative stimulus effects was 0.013 mg/kg. Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding. Mecamylamine and dihydro-β-erythroidine (DHβE) dose-dependently attenuated the discriminative stimulus effects of the nicotine training dose, whereas methyllycaconitine (MLA) did not. DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45). Compared to human cigarette smoking, nicotine blood levels after 0.032 mg/kg nicotine i.v. took a similar time to reach maximal concentration, levels at Cmax were similar to smoking 2-3 cigarettes, while average nicotine levels were comparable to smoking 5-6 cigarettes. Apparent pA2 analysis with DHβE under these conditions is consistent with nicotine and varenicline acting through the same nAChRs to produce discriminative stimulus effects.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DHβE; Drug discrimination; FR; MLA; Nicotine; Rhesus monkey; Schild analysis; Varenicline; dihydro-β-erythroidine; fixed ratio; methyllycaconitine; nAChR; nicotinic acetylcholine receptor

Mesh:

Substances:

Year:  2016        PMID: 27940077      PMCID: PMC5385163          DOI: 10.1016/j.neuropharm.2016.12.003

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  31 in total

1.  Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras.

Authors:  Roger L Papke; Linda P Dwoskin; Peter A Crooks; Guangrong Zheng; Zhenfa Zhang; J Michael McIntosh; Clare Stokes
Journal:  Neuropharmacology       Date:  2008-03-28       Impact factor: 5.250

2.  Acute and chronic effects of the neuroactive steroid pregnanolone on schedule-controlled responding in rhesus monkeys.

Authors:  L R McMahon; C P France
Journal:  Behav Pharmacol       Date:  2002-11       Impact factor: 2.293

3.  Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement.

Authors:  Cecilia Gotti; Stefania Guiducci; Vincenzo Tedesco; Silvia Corbioli; Lara Zanetti; Milena Moretti; Alessio Zanardi; Roberto Rimondini; Manolo Mugnaini; Francesco Clementi; Christian Chiamulera; Michele Zoli
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

Review 4.  Metabolism and disposition kinetics of nicotine.

Authors:  Janne Hukkanen; Peyton Jacob; Neal L Benowitz
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

5.  Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice.

Authors:  J Gommans; I P Stolerman; M Shoaib
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

6.  The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion.

Authors:  M Shoaib; J Gommans; A Morley; I P Stolerman; R Grailhe; J-P Changeux
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

7.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

8.  Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice.

Authors:  Jesse S Rodriguez; Colin S Cunningham; Fernando B Moura; Pauline Ondachi; F Ivy Carroll; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.

Authors:  Jun-Xu Li; Lance R McMahon; Lisa R Gerak; Ginger L Becker; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2008-05-10       Impact factor: 4.530

View more
  7 in total

1.  Stimulus functions of nicotine.

Authors:  Mark G LeSage
Journal:  Adv Pharmacol       Date:  2022-01-12

Review 2.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

Review 3.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

4.  Enhancement of Opioid Antinociception by Nicotine.

Authors:  Fernando Barreto de Moura; Sarah Louise Withey; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2019-09-16       Impact factor: 4.030

5.  Rapid nicotine tolerance and cross-tolerance to varenicline in rhesus monkeys: Drug discrimination.

Authors:  Megan J Moerke; Lance R McMahon
Journal:  Exp Clin Psychopharmacol       Date:  2018-08-13       Impact factor: 3.157

6.  Enhancement of Opioid Antinociception by Nicotinic Ligands.

Authors:  Fernando B de Moura; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2021-01-13       Impact factor: 4.030

7.  Effects of nicotinic antagonists on working memory performance in young rhesus monkeys.

Authors:  Nicholas A Upright; Mark G Baxter
Journal:  Neurobiol Learn Mem       Date:  2021-08-20       Impact factor: 3.109

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.